ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 1.86 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-12
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 0.00 shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 1.86M shares, a 72.94% increase year-over-year.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 0.00 shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 0.00 shares.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 1.07M shares, a 78.05% increase from fiscal 2024.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 602.60K shares, a 141.41% increase from fiscal 2023.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 249.62K shares, a 58.71% decline from fiscal 2022.
- ANNEXON, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 604.58K shares, a 1109.17% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 1.86M shares 10-Q · filed 2026-08-12 | 1.86M shares derived: sum of 3 quarters · filed 2026-08-12 | 1.86M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 1.86M shares 10-Q · filed 2026-05-07 | 1.86M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.86M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.86M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-30 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-30 | 1.07M shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-10 | 1.07M shares 10-Q · filed 2025-11-10 | 1.07M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 1.07M shares 10-Q · filed 2025-08-14 | 1.07M shares derived: sum of 3 quarters · filed 2025-08-14 | 1.07M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 1.07M shares 10-Q · filed 2025-05-12 | 1.07M shares derived: sum of 2 quarters · filed 2025-05-12 | 1.07M shares derived: sum of 3 quarters · filed 2025-05-12 | 1.07M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-03 | 0.00 shares derived: sum of 3 quarters · filed 2025-03-03 | 602.60K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-14 | 602.60K shares 10-Q · filed 2024-11-14 | 602.60K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 602.60K shares 10-Q · filed 2024-08-12 | 602.60K shares derived: sum of 3 quarters · filed 2024-08-12 | 602.60K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 602.60K shares 10-Q · filed 2024-05-13 | 602.60K shares derived: sum of 2 quarters · filed 2024-05-13 | 602.60K shares derived: sum of 3 quarters · filed 2024-05-13 | 602.60K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-26 | 0.00 shares derived: sum of 3 quarters · filed 2024-03-26 | 249.62K shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-13 | 249.62K shares 10-Q · filed 2023-11-13 | 253.62K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 249.62K shares 10-Q · filed 2023-08-07 | 253.62K shares derived: sum of 3 quarters · filed 2023-08-07 | 559.57K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 249.62K shares 10-Q · filed 2023-05-08 | 253.62K shares derived: sum of 2 quarters · filed 2023-05-08 | 559.57K shares derived: sum of 3 quarters · filed 2023-05-08 | 559.57K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 4.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 309.95K shares derived: sum of 2 quarters · filed 2023-03-06 | 309.95K shares derived: sum of 3 quarters · filed 2023-03-06 | 604.58K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 305.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 305.95K shares derived: sum of 2 quarters · filed 2022-11-03 | 600.58K shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 294.63K shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 294.63K shares 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 50.00K shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |